







Therapy	Target/Modality	Indications	Preclinical	Phase 1	Phase 2	Phase 2 Reg / Phase 3
Rigosertib	PLK1/PI3K Small molecule	MDS				
Magrolimab + Azacitidine	Anti-CD47 Antibody	MDS				
Magrolimab + Rituximab	Anti-CD47 Antibody	DLBCL				
AFM13	CD30/CD16A Bispecific Engager	PTCL				
CPI-0610 +/- Ruxolitinib	BET Small molecule	MPN				planned
ARGX-110 +/- Azacitidine or Ven	Anti-CD70 Antibody	AML				
Duvelisib + Romidepsin	PI3Kδ/γ Small molecule	PTCL				
Cobomarsen	miR-155 Small molecule	CTCL				
Fimepinostat + Ven or Rux/Benda	HDAC/PI3K Small molecule	DLBCL				
X4P-001 + Ibrutinib	CXCR4 Small molecule	Waldenström's				
K-NK002	NK Cell Therapy	AML/MDS				
SEL120	CDK8/19 Small molecule	AML/MDS				
PCX-410 + ACY-241 +/- Len	Vaccine	Smoldering myeloma				
STRO-001	Anti-CD74 Antibody	MM/DLBCL/MCL/FL				
Pinometostat + Aza or SOC	DOT1L Small molecule	MLL leukemia				
CAR-37	T Cell Therapy	B-cell lymphoma/ T-cell lymphoma				
BTX-A51	CK1-α/CDK7/CDK9 Small molecule	AML/MDS				
NK-cells + ALT-803	NK Cell Therapy	Heme malignancies				
KO-539	Menin Small molecule	MLL leukemia				
NEXI-001	T Cell Therapy	AML				
PROTACs	IRAK4/STAT3 Small molecule	Lymphoma				